tebentafusp-tebn (Kimmtrak)
Jump to navigation
Jump to search
Indications
Mechanism of action
- T-cell receptor bispecific immunotherapy
- bispecific gp100 peptide-HLA-directed CD3 T-cell engager
- has high-affinity T-cell receptor binding domain & an anti-CD3 T-cell engaging domain, which redirects T cells to kill gp100-expressing tumor cells
- the T-cell receptor binding domain only recognizes a specific gp100-derived peptide presented on HLA-A*02:01, thus tebentafusp can only be used to treat patients with this HLA type.
- bispecific gp100 peptide-HLA-directed CD3 T-cell engager
More general terms
References
- ↑ Chustecka Z Novel Drug, First Tx Approved for Rare Uveal Melanoma. Medscape. Jan 27, 2022 https://www.medscape.com/viewarticle/967360
- ↑ Nathan P, Hassel JC, Rutkowski P et al Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med 2021; 385:1196-1206 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34551229 Free article https://www.nejm.org/doi/full/10.1056/NEJMoa2103485